“SORTI”ing Out the Benefits of Leveraging SORT1 Targeting PDC to Unlock New Therapeutic Options in Oncology
Time: 8:30 am
day: Day Two
Details:
- Discussing the SORT 1 receptor in cancer as a novel target and how exploitation of one of its main biological functions as a sorting/trafficking/scavenger protein facilitates rapid internalization of its ligands, within minutes, to deliver cytotoxic payloads inside cancer cells
- Considering the unique MOA and safety profile of TH1902, its potential for combination with other anti-cancer agents to improve efficacy outcomes, and discuss how it triggers immune infiltration via the cGAS/STING pathway to potentiate anti-PD-L1 immune mediated tumor cell killing
- Reviewing the discovery path of TH1902, from bench to bedside, and leverage the lessons learned to facilitate development of new SORT1 targeting PDC conjugates
